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Abstract
Aims/hypothesis ZBED6 (zinc finger, BED-type containing 6) is known to regulate muscle mass by suppression of Igf2 gene
transcription. In insulin-producing cell lines, ZBED6 maintains proliferative capacity at the expense of differentiation and beta cell
function. The aim was to study the impact of Zbed6 knockout on beta cell function and glucose tolerance in C57BL/6 mice.
Methods Beta cell area and proliferation were determined in Zbed6 knockout mice using immunohistochemical analysis. Muscle
and fat distribution were assessed using micro-computed tomography. Islet gene expression was assessed by RNA sequencing.
Effects of a high-fat diet were analysed by glucose tolerance and insulin tolerance tests. ZBED6 was overexpressed in
EndoC-βH1 cells and human islet cells using an adenoviral vector. Beta cell cell-cycle analysis, insulin release and mitochondrial
function were studied in vitro using propidium iodide staining and flow cytometry, ELISA, the Seahorse technique, and the
fluorescent probes JC-1 and MitoSox.
Results Islets from Zbed6 knockout mice showed lowered expression of the cell cycle gene Pttg1, decreased beta cell proliferation
and decreased beta cell area, which occurred independently fromZBED6 effects on Igf2 gene expression. Zbed6 knockout mice, but
not wild-type mice, developed glucose intolerance when given a high-fat diet. The high-fat diet Zbed6 knockout islets displayed
upregulated expression of oxidative phosphorylation genes and genes associated with beta cell differentiation. In vitro, ZBED6
overexpression resulted in increased EndoC-βH1 cell proliferation and a reduced glucose-stimulated insulin release in human islets.
ZBED6 also reducedmitochondrial JC-1 J-aggregate formation, mitochondrial oxygen consumption rates (OCR) andmitochondrial
reactive oxygen species (ROS) production, both at basal and palmitate + high glucose-stimulated conditions. ZBED6-induced
inhibition of OCR was not rescued by IGF2 addition. ZBED6 reduced levels of the mitochondrial regulator PPAR-γ related
coactivator 1 protein (PRC) and bound its promoter/enhancer region. Knockdown of PRC resulted in a lowered OCR.
Conclusions/interpretation It is concluded that ZBED6 is required for normal beta cell replication and also limits excessive beta cell
mitochondrial activation in response to an increased functional demand. ZBED6 may act, at least in part, by restricting PRC-mediated
mitochondrial activation/ROS production, which may lead to protection against beta cell dysfunction and glucose intolerance in vivo.
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ROS Reactive oxygen species
RPKM Reads per kilobase million
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Introduction
ZBED6 (zinc finger, BED-type containing 6) is a transcriptional
modulator that is unique to placental mammals and has evolved
from a DNA transposon that integrated in an ancestor of
mammals more than 200 million years ago [1]. The fact that the
DNA-binding domain of ZBED6 was found to show 100%
sequence identity among 25 placental mammals implies that it
serves an essential function. ZBED6 acts as a repressor of Igf2
expression in multiple tissues through the binding of the GCTCG
motif located in an intron of Igf2 [1, 2]. The ZBED6-mediated
lowering of Igf2 expression results not only in decreased muscle
mass, but also affects the size of organs such as the liver, kidney
and heart [3]. ZBED6 is also expressed in insulin-producing beta
cells, where it has been shown to modulate reactive oxygen
species (ROS) production, insulin production, proliferation and
cell death [4]. In vitro, ZBED6 seems to maintain the capacity of
beta cells to proliferate at the expense of specialised function,
negatively affecting cell-to-cell interactions [5], stimulus-
secretion coupling involving cAMP and Ca2+ signalling events,
and neuronal/beta cell differentiation pathways [6]. Thus, it is
possible that ZBED6 controls the balance between proliferation
and function/differentiation of beta cells, thereby preventing either
process from unwanted domination. Indeed, in early stages of the
pathogenesis of type 2 diabetes, beta cells are often hyperactivated
in response to hyperglycaemia, hyperlipidaemia or inflammatory
signals [7], leading to hyperinsulinaemia [8]. Later, as peripheral
insulin resistance develops and the insulin requirement augments
further, the beta cell mass fails to adapt by proliferation [9], and
instead de- or transdifferentiate [10], or even undergo apoptosis
[11], leading to a worsened glucose homeostasis. This may
suggest that initial activation traps the beta cells in a non-
proliferative state, which does not allow expansion of the beta
cell mass under conditions of continued and intensified stimula-
tion, subsequently causing beta cell damage [12]. Therefore,
ZBED6 may be a factor that modulates the balance between
proliferation and function. Consequently, in this study we aimed
to evaluate the effects of the transcriptional modulator ZBED6 on
beta cell proliferation and function in vivo and in vitro.
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Methods
Animals and high-fat diet treatment The Zbed6−/− and Igf2pA/
mG models were generated by homologous recombination in
mouse Nnt+/+ C57BL/6 embryonic stem cells as previously
described [3], without affecting the host gene Zc3h11a [13].
The two transgenic mouse models were both maintained on a
C57BL/6 background and bred to generate Zbed6+/+ Igf2G/G
(wild-type [WT] G), Zbed6−/− Igf2G/G (knockout [KO] G),
Zbed6+/+ Igf2pA/mG (WT G/A) and Zbed6−/− Igf2pA/mG (KO
G/A) mice. The G to A mutation in the ZBED6 binding site in
the Igf2 intronic CpG island abolishes ZBED6 binding and
was present on the paternal chromosome, as Igf2 is only pater-
nally expressed.
At 5weeks of age,Zbed6KOGandWTGmice (both female
and male) were divided into two groups with 16 mice in each.
One groupwas given a control diet (CD) and the other was given
a high-fat diet (HFD). TheHFD (D12492, Research Diets, USA)
contained 60% energy from fat, whereas the CD (D12450B,
Research Diets) contained only 10% energy from fat.
Ethics permission and animal welfare All animals were group-
housed with free access to food and water in the pathogen-free
facilities of Uppsala University and Karolinska Institute. All
procedures described in this study were approved by the
Uppsala Ethical Committee on Animal Research (#C63/15 and
#C143/15) and the Stockholm Ethical Committee (#N38/15),
following the rules and regulations of the Swedish Animal
Welfare Agency, and were in compliance with the European
Communities Council Directive of 22 September 2010
(2010/63/EU). All efforts were made to minimise animal suffer-
ing and to reduce the number of animals used.
Blood glucose tolerance test The mice, after having fasted for
approximately 8 h, were given a single i.p. dose of 2.5 g/kg
body weight of 30% wt/vol. D-glucose. Blood was drawn
from the tail and measured with Freestyle Mini System
(Abbott, TheraSense, USA). Blood glucose was determined
prior to injection and then at 10, 30, 60 and 120 min after
injection.
Insulin sensitivity testMicewere given an i.p. injection (1.6U/
kg body weight) of the insulin analogue Actrapid (Novo
Nordisk, Bagsværd, Denmark). The animals had free access
to food before the insulin injection and were transferred to
new cages without food during the measurements.
Micro-computed tomography After 10 weeks on a CD or
HFD (15–17 weeks of age) the mice were scanned by
micro-computed tomography (micro-CT) (Bruker, USA)
directly after euthanasia. The scanning protocol was set using
voltage 50 kV, current 500 μA and exposure time 60 ms. We
scanned at 36 μm with filter Al 0.5 mm, rotation step 0.7, and
two connected scans with a total duration time of 3 min 30 s.
The amount of abdominal fat was analysed by reconstructing
the whole scan in NRecon. In CTAn the volume of interest
was determined by the start and end points of the lumber
vertebrae. The amount of fat and muscle between vertebrae
L6–L4 was analysed.
Immunohistochemistry Pancreatic sections, 5 μm thick, were
immunostained as previously described [4]. Sections were
incubated with primary antibodies (guinea pig anti-human
insulin, [1:3000; Reactionlab, USA], anti-glucagon and anti-
Ki-67 [1:250, Abcam, UK]) overnight at 4°C. The secondary
antibodies (highly cross-adsorbed Alexa Fluor 633 goat anti-
guinea pig [1:500; Life Technologies, USA], highly cross-
adsorbed Alexa Fluor 555 goat anti-rabbit [1:500; Life
Technologies], Alexa Fluor 647 donkey anti-rabbit [1:200,
Jackson ImmunoResearch Laboratories, UK]) were added
for 1 h. The total pancreas area for each section was measured
using ImageJ and a mean for all sections for each mouse,
expressed in arbitrary units, was calculated. Beta cell (and
alpha cell) mass was semi-quantified similarly and expressed
as a ratio to the total pancreas area obtained for the same
section. Number of Ki-67-positive beta and alpha cells were
counted and expressed as ratio to total number of beta and
alpha cells in the same section. At least 30 islets per pancreas,
located at three different regions of the pancreas, were
analysed.
Quantitative real-time PCR analysis Pancreatic islets fromWT
G and Zbed6 KO G C57BL/6 mice were prepared by collage-
nase digestion and cultured overnight as previously described
[14]. RNA was purified from islet cells using the Qiagen
RNeasy kit (Qiagen, Hilden, Germany), and cDNA was
synthesised using avian myeloblastosis virus (AMV) reverse
transcriptase (Bio-Rad, Hercules, CA, USA). Real-time q-
PCR was performed using the Roche Light Cycler System
and the FastStart DNA Master DNA SYBR Green I kit
(Roche Diagnostics, Mannheim, Germany). Values were
normalised to the relative amounts of GAPDH cDNA.
Primer sequences can be found in electronic supplementary
material (ESM Table 1).
Whole transcriptome analysis Strand-specific mRNA
sequencing libraries were generated using the QuantSeq 3′
mRNA-seq library prep kit (Lexogen, Austria). 100 ng of total
RNAwas poly-A selected using magnetic beads. The libraries
were sequenced as 50 bp single reads using an Illumina HiSeq
instrument (Illumina, USA). Sequence reads were mapped to
the reference mouse genome (mm10) using STAR 2.5.1b.
HTSeq-0.6.1 package was used to generate read counts and
edgeR package was used to analyse differentially expressed
genes. The gene expression was normalised by trimmed mean
of M-values method [15] and the abundance of gene
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expression was calculated as count-per-million reads. For
gene ontology analysis, the differentially expressed genes
were analysed using the ClusterProfiler R package [16].
Mitochondrial ROS and membrane potential analysis
Mycoplasma free βTC-6 (RRID: CVCL_0605) and MIN6
(RRID: CVCL_0431) cells were cultured as previously
described [4, 6]. Cells were cultivated in 24-well plates
(Falcon, USA) to a density about 5 × 105 cells/well. In exper-
iments, cells were treated with sodium palmitate (0.5 mmol/l
in 0.5% fatty acid free BSA) + 20 mmol/l glucose. Human
EndoC-βH1 (RRID: CVCL_L909) cells were cultured as
previously described [17].
Cells were labelled with 1 μmol/l MitoSOX (Thermo Fisher,
USA) for 60 min. Cells were then trypsinised and red fluores-
cence (FL2) was measured using a flow cytometer. For the anal-
ysis of mitochondrial membrane potential, cells were labelled
with 5 μmol/l of the fluorescent probe JC-1 (Thermo Fisher),
which is activated in the mitochondrial matrix when the
membrane is hyperpolarised [18], for 30 min. The ratio between
the 585 and 530 nm signals was calculated to monitor changes in
mitochondrial membrane potential.
Immunoblotting Immunoblotting was performed as previous-
ly described [4]. The following primary antibodies were used:
mouse anti-PRC (1:400; Santa Cruz Biotechnology, USA),
rabbit anti-human phospho-PGC1α (S571) (1:200; R & D
systems, USA), and mouse anti-α-tubulin (TU-02) (1:500,
Santa Cruz). Fluorescent anti-mouse/rabbit secondary anti-
bodies were from Abcam (1:15,000). The bound antibodies
were visualised with a LI-COR Odyssey Fc system (LI-COR
Biosciences, Lincoln, USA).
Adenoviral-mediated ZBED6 overexpression We used an
adenoviral vector expressing human ZBED6 protein
(untagged) behind the cytomegalovirus (CMV) promoter
from Applied Biological Materials (Abm, Canada). An
adenoviral vector without any protein expression was used
as a control virus. Virus stocks were purified by caesium
chloride density-gradient centrifugation (L-80 ultracentri-
fuge; Beckman Coulter, Fullerton, CA, USA) and semi-
quantified by titration. For the adenoviral-mediated trans-
duction, EndoC-βH1 cells were incubated at 37°C for 1 h in
a volume of 0.4 ml RPMI-1640 supplemented with 2% FCS
and adenoviral vectors at equal concentrations. Two and 3
days after transfection with viral particles at a concentration
of 10 and 50 multiplicity of infection (MOI), cells were
fixed in ethanol (−20°C) and then stained for 20 min in 5
μg/ml propidium iodide. Cell cycle phases were analysed
by flow cytometry.
Adenoviral vectors (10 and 50 MOI) were also used for
transduction of human islets. Permission to obtain pancreatic
islet tissue from the Nordic Network for Clinical Islet
Transplantation was reviewed and approved by the local
ethics committee (Regionala etikprövningsnämnden,
Uppsala) in Uppsala, Sweden. Human islets were cultured
free-floating in Sterilin dishes in CMRL 1066 medium (ICN
Biomedicals, Costa Mesa, CA, USA) containing 5.6 mmol/l
glucose, 10% FCSand 2 mmol/l L-glutamine for 1–5 days and
then dispersed by trypsin treatment for 7–8 min. Dispersed
cells were then transduced as given above. Three days after
the transduction procedure islet cells were incubated for 60
min in 1.7 mmol/l glucose and an additional 60 min in 17
mmol/l glucose. Insulin release was determined using an
ELISA (Mercodia, Sweden).
Oxygen consumption ratesOxygen consumption rates (OCR)
and extracellular acidification rate (ECAR), which usually
represents glycolytic rates, in EndoC-βH1 cells were
measured by Extracellular Flux Analyzer XFe96 (Seahorse
Bioscience, USA) as previously described [19]. EndoC-βH1
cells were transduced with adenoviral vectors, and after a 48 h
culture period, assayed for OCR and ECAR in 5.6 mmol/l
glucose, combination of palmitate (1.5 mmol/l with 2%
BSA) and high glucose (20 mmol/l), or mouse IGF2 100
ng/ml (R & D Systems) for 1 h.
Statistical analysis SigmaStat 4.0 (SYSTAT, USA) was used
for all statistical computations. Results are given as means ±
SEM. The differences between two groups were determined
by Student’s paired t test. For multiple comparisons repeated
Fig. 1 Islet size and beta cell area are reduced in Zbed6KOG and Zbed6
KO G/A mice and Zbed6 KO promotes HFD-induced glucose
intolerance. WT G, KO G, WT G/A and KO G/A mice were killed
when 25–28 weeks of age and analysed for (a) total pancreas area, (b)
islet number, (c) islet size, (d) beta cell area, (e) beta cell proliferation and
(f) alpha cell proliferation. Results are means ± SEM for 6–9 mice per
group. *p < 0.05 vs corresponding WT mice. (g) Weight curve of WT G
and KO G mice given a CD or an HFD from 6 to 15 weeks of age; 7–8
mice per group were analysed. (h) Micro-CT was performed on the mice
shortly after euthanasia and fat andmuscle mass was quantified; 3–5mice
per group were analysed. (i) GTT of WT G and KO G mice treated with
HFD or CD. Mice were fasted for 8 h and injected intraperitoneally with
glucose (2.5 g/kg). Blood glucose levels were analysed at the time points
given. Results are means ± SEM for 6–8 mice in each group. (j) Data
from (i) were recalculated to AUC. *** p < 0.001 vs KO mice given a
CD. (k) Insulin sensitivity test of WT G and KO G mice treated for 9
weeks with an HFD. Insulin (1.6 U/kg Actrapid) was injected i.p. and
blood glucose was analysed at the time points given in the figure. Results
are means ± SEM for 6–8 mice in each group. (l) Beta cell area was
assessed by morphometric analysis. ** p < 0.01 vs WT CD (n; = 6–8
mice). (m) Representative immunostainings showingmorphology of beta
cells (insulin, green), alpha cells (glucagon, green) and Ki-67 positive
cells (red). Arrows point to two Ki-67 positive beta/alpha cells. White
scale bars, 100 μm. (n) Alpha cell area was assessed by morphometric
analysis (n = 6–8 mice). Beta cell (o) and alpha cell (p) replication was
assessed by Ki-67 immunostaining. ** p < 0.01 vsWT CDmice (n = 6–8
mice)
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measurements two-way ANOVA followed by Student
Newman Keuls post hoc test was used.
Results
Knockout of Zbed6, but not knockin of Igf2, results in
reduced beta cell area The Zbed6 KO mice were generated
using the C57BL/6 embryonic stem cell line Bruce4 [20],
which are Nnt+/Nnt+ as assessed by RNA sequencing (RNA-
Seq) analysis of the Nnt transcripts (ESM Fig. 1). The general
characteristics of the Zbed6 KO and Igf2 knockin mice have
been recently characterised [3]. To specifically study insulin-
producing beta cells, we euthanised Zbed6+/+ Igf2G/G (WTG),
Zbed6−/− Igf2G/G (KO G), Zbed6+/+ Igf2pA/mG (WT G/A) and
Zbed6−/− Igf2pA/mG (KO G/A) mice when 25–28 weeks of
a b c d
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age. WT G mice express ZBED6 and low levels of IGF2, the
KO G mice lack ZBED6 and express high IGF2 levels, the
WT G/A mice do not lack ZBED6 but express high IGF2
levels, and the KO G/A mice lack ZBED6 and express high
IGF2 levels [3]. Presently, the total pancreas area and the
number of islets per total pancreas area were not affected by
ZBED6 or IGF2 (Fig. 1a,b). However, the mean islet size, as
well as the beta cell area per total pancreas area, were reduced
in both KOG and KOG/Amice (Fig. 1c,d). Thus, the reduced
beta cell area occurred in response to Zbed6 KO and indepen-
dently from Igf2 expression. Despite this lowered beta cell
area, neither alpha- nor beta cell proliferation were decreased
by Zbed6 KO or Igf2 knockin (Fig. 1e,f).
Zbed6 KO promotes glucose intolerance in HFD-fed mice
Both WT G and KO G mice, 5–7 weeks old, were given a
control diet (WT CD and KO CD, respectively) or an HFD
(WT HFD and KO HFD, respectively) for 10 weeks. These
mice are anticipated to present a mild beta cell phenotype
[21]. The HFD increased the weight of WT G mice, but not
of KO G mice (Fig. 1g). The weight of KO G mice was higher
than that ofWTGmice at start of the HFD, which is in line with
a previous report stating that muscle and internal organ mass is
increased in KOmice [3]. Indeed, using micro-CT we observed
an augmented muscle mass of KO CD as compared with WT
CD at the level corresponding to the lumbar vertebrae 4 to 6
(L4-L6) (Fig. 1h). In HFD mice, however, this effect was
abolished (Fig. 1h).
As in a previous study [3], a GTT showed that KO CD mice
responded similarly to the glucose injection as WT CD mice
(Fig. 1i). The GTT of WT CD andWT HFD mice were similar.
The glucose levels of KO HFDmice were, however, augmented
when compared with WT HFD mice (Fig. 1i). Furthermore,
calculations of the AUC showed that KO worsened the glucose
tolerance in HFD mice (Fig. 1j). We also performed an ITT and
observed no differences between the different groups (Fig. 1k),
suggesting that neither the 10-week HFD, nor the Zbed6 KO,
affected peripheral insulin sensitivity.
The beta cell area was decreased in KO CD mice as
compared with WT CD mice (Fig. 1l), which is in line with
the findings with older KOGmice (25–28 weeks) (Fig. 1d). A
representative picture ofWTG and KOG islets shows that the
morphology and size of islet cells was not affected (Fig. 1m).
This was paralleled by a lowered beta cell replication rate in
the younger (15–17 weeks) KO CD mice (Fig. 1o). This
lowering effect by Zbed6 KO was not observed in HFD-
treated mice. There was a non-significant trend to similar
effects of Zbed6 KO on alpha cells (Fig. 1n and p).
Fig. 2 Zbed6 KO results in decreased islet expression of Pttg1 and
increased expression of oxidative phosphorylation genes when given an
HFD. Islets from 3–4 mice in each group were isolated and analysed by
RNA-Seq. (a) Heat map of the top 100 differentially expressed genes
(DEs) inWTHFD vsKOHFD islets, colour scale represents their expres-
sion across groups. (b) Gene ontology analysis of the upregulated differ-
entially expressed genes in KO HFD. (c, d) Pttg1 mRNA expression, as
analysed by RNA-Seq (counts per min [CPM]) (c) and qPCR (d)
2297Diabetologia  (2021) 64:2292–2305
Zbed6 KO reduces Pttg1 and increases levels of mRNAs
coding for mitochondrial oxidative phosphorylation proteins
when exposed to an HFD RNA-Seq analysis of Zbed6-KO G
and WT G islets, under CD conditions, revealed up- and
downregulation of only six and two genes, respectively
(False discovery rate [FDR] < 0.05, Fig. 2a). In contrast,
during HFD treatment there was upregulation of 377 genes
and downregulation of 409 genes (Fig. 2a, ESM Table 2).
Among the downregulated genes we observed that the cell
cycle gene Pttg1 was reduced by almost 90% in the KO islets
(ESM Table 2 and Fig. 2c), which was confirmed using RT-
qPCR (Fig. 2d). Chromatin immunoprecipitation sequencing
(ChIP-seq) using the mouse MIN6 beta cell line indicated a
binding site of ZBED6 in the Pttg1 gene (ESM Fig. 2). In
addition to Pttg1, we also observed a lowered expression of
the cell cycle protein cyclin C (Table 1 and ESM Table 2).
Other noteworthy upregulated genes were Ins1/2, Pcsk2 and
Glut2/Slc2a2, all essential for insulin production (ESM Fig. 3
and Table 1). Beta cell transcription factors, Nkx6-1, FoxO1
and Pax6 [22], were increased in KO islets (Fig. 2a and
Table 1), concurring with previous studies [4, 6]. Also in line
with previous reports [5], E-cadherin was downregulated, and
N-cadherin and the cAMP-generating enzyme Adcy9 were
upregulated (Table 1). The most important beta cell
autoantigens in type 1 diabetes (Ins1/2, Slc30a8, Ica1,
Gad1, Ptprn2) were expressed at higher levels in Zbed6-KO
islets. Among the upregulated genes in the HFD conditions
we observed also Igf2, which confirms that ZBED6 acts as a
repressor of Igf2 expression in islet cells (Table 1).
Gene ontology enrichment (GOE) analysis of the KO
differentially expressed genes in HFD conditions showed
clustering (FDR < 0.05) in the category oxidative phosphor-
ylation among the upregulated genes (Fig. 2b). The 13 genes
belonging to this category are shown in ESM Table 3. This
was paralleled by increased expression of uncoupling
protein 2 (Ucp2) and reactive oxygen species modulator
1 (Romo1) (Table 1), two proteins involved in mito-
chondrial ROS production and protection from ROS
[23, 24].
ZBED6 decreases EndoC-βH1 cell basal and maximal OCRWe
next determined EndoC-βH1 cell OCR at basal (no addition)
and carbonyl cyanide-p-trifluoromethoxyphenylhydrazone
(FCCP)-stimulated (maximal OCR) conditions 2 days after
ZBED6 adenoviral transduction (Fig. 3a). ZBED6 adenoviral
particles increased ZBED6 protein levels in EndoC-βH1 beta
cells without signs of cytotoxicity (Fig. 3a, results not shown)
and generated an approximate tenfold increase in ZBED6
mRNA expression (Fig. 3b). ZBED6 overexpression was
associated with a lowered IGF2mRNA level and an increased
PTTG1mRNA level (Fig. 3b). ZBED6 overexpression result-
ed in lower basal and maximal OCR as compared with control
Table 1 Genes affected by Zbed6 knockout in mice. Validations from in vitro beta cell studies were also included
Cellular process Gene symbol Gene name Comment/Reference
Insulin production Ins1 Insulin 1 Upregulated [4, 6]
Ins2 Insulin 2 Upregulated [4, 6]
Pcsk2 Proprotein convertase subtilisin/kexin type 2 Upregulated
Slc2a2 Solute carrier family 2 (facilitated glucose transporter), member 2 Upregulated
Transcription factors Nkx6-1 NK6 homeobox 1 Upregulated [6]
Foxo1 Forkhead box O1 Upregulated
Pax6 Paired box gene 6 Upregulated [6]
Cell cycle Pttg1 Pituitary tumour-transforming gene 1 Downregulated
Ccnc Cyclin C Downregulated
Beta cell autoantigens Ins1/2 Insulin 1/Insulin 2 Upregulated
Slc30a2 Solute carrier family 30 (zinc transporter), member 8 Upregulated
Ica1 Islet cell autoantigen 1 Upregulated
Gad1 Glutamic acid decarboxylase 1 Upregulated
Ptprn2 Protein tyrosine phosphatase, receptor type, N polypeptide 2 Upregulated
Cell–cell contacts Cdh1 Cadherin 1 (E-cadherin) Downregulated [5]
Cdh2 Cadherin 2 (N-cadherin) Upregulated [5]
cAMP-signalling Adcy9 Adenylate cyclase 9 Upregulated [6]
Mitochondrial ROS Romo1 Reactive oxygen species modulator 1 Upregulated
Ucp2 Uncoupling protein 2 (mitochondrial, proton carrier) Upregulated
Miscellaneous: Igf2 Insulin-like growth factor 2 Upregulated
Zbed6 Zinc finger, BED-type containing 6 Downregulated
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virus exposed cells (Fig. 3c,d). IGF2 addition for 1 h stimu-
lated both basal and maximal OCR in control cells, but not in
ZBED6 cells. ECAR was unaffected by ZBED6, and was
stimulated by IGF2 in control cells, but not in ZBED6 cells
(Fig. 3d). Thus, ZBED6 restricts respiration, but not via
repression of the IGF2 gene.
We also analysed effects of ZBED6 overexpression in cells
stimulated by palmitate (1.5 mmol/l) and high glucose (20
mmol/l) for 1 h. Addition of palmitate and high glucose
increased ECAR and reduced basal OCR (Fig. 3e,f), indicating
that EndoC-βH1 cells have a high capacity to upregulate glyco-
lytic ATP production in response to a high glucose concentra-
tion (Warburg effect). However, in the presence of FCCP,
maximal respiration was increased by palmitate and high
glucose in control cells (Fig. 3f), suggesting that palmitate and
high glucose can further stimulate respiration at conditions of
low mitochondrial ATP. ZBED6 promoted a lowered maximal
OCR with and without palmitate and high glucose (Fig. 3f).
ZBED6 overexpression also affected EndoC-βH1 cell
proliferation as assessed by analysis of the distribution of cells
in the different cell cycle phases. We observed that the fraction
of cells in the S phase was increased 2 days after transduction at
the concentration of 50 MOI (Fig. 3g). Three days after trans-
fection, the fraction of cells in G1 and G2/M were decreased
and increased, respectively, by ZBED6 (Fig. 3h), suggesting
that ZBED6 promotes increased proliferation.
To analyse whether ZBED6 affects glucose-induced
insulin release we transduced dispersed human islets with
ZBED6 adenoviral vectors. After 3 days, the higher
concentration of the vector (50 MOI) resulted in a
lowered insulin release at 17 mmol/l glucose (Fig. 3i).
This resulted in a lowered glucose-stimulated insulin
release ratio (Fig. 3j).
ZBED6 reduces mitochondrial membrane potential and
mitochondrial ROS production We next transfected
EndoC-βH1 cells with a ZBED6-GFP expression vector and
immunostained for respiratory chain protein ATPase inhibitory
factor 1 (ATPIF1), a mitochondrial marker protein, which allows
visualisation of mitochondrial density andmorphology. ZBED6-
GFP-positive cells displayedmitochondria with similar morphol-
ogy and number as those of non-GFP-positive cells 2 days after
transfection (ESM Fig. 4). However, when cells were stained
with JC-1, which emits red J-aggregate light when the
inner membranes of mitochondria are polarised, GFP-
positive cells showed fewer J-aggregate positive mito-
chondrial structures than GFP-negative cells (Fig.
4a,b). Also, MitoTracker Red uptake into mitochondria
of GFP-positive cells was lower than that of GFP-
negative cells (Fig. 4a,b). This supports the hypothesis
tha t ZBED6 lowers mitochondr ia l act ivi ty , as
MitoTracker Red is not efficiently taken up by inactive
mitochondria. Mitochondrial ROS production, assessed
using the MitoSOX probe, was lower in ZBED6-
overexpressing EndoC-βH1 cells cultured with palmitate
and high glucose (Fig. 4c).
Zbed6 knockdown results in increased OCR, J-aggregate
formation and mitochondrial ROS production Zbed6 was
knocked down in MIN6 cells by using anti-Zbed6 short hairpin
RNA (shRNA) lentiviral particles [4–6]. As control cells we used
scramble shRNA lentiviral-transduced cells (neg) and found that
Zbed6 knockdown (sh1) resulted in higher basal and maximal
OCR (Fig. 4d). Also, ECAR was higher in sh1 cells than in neg
cells (Fig. 4d). The increased OCR of sh1 cells was observed at
both 5 mmol/l and 25 mmol/l glucose.
Silencing of Zbed6 was also performed in insulin-producing
βTC-6 cells [4], and in this case the Zbed6 knockdown sh1, sh2
and sh1+sh2 cells displayed increased JC-1 J-aggregate
Fig. 3 ZBED6 overexpression reduces mitochondrial respiration and
glucose-induced insulin release. (a) EndoC-βH1 cells were transduced
with control (no protein expression) or ZBED6 adenoviral particles and
analysed after 2 days by immunoblotting for ZBED6 protein levels. An
adenoviral vector without transgene protein expression was used as
control virus 1. Control virus 2 was a SIRT1-expressing adenoviral
vector. The immunoblot is representative for three observations. α-
Tubulin (Tub) was used as a control. (b) EndoC-βH1 cells were
transduced with control (no protein expression) or ZBED6 adenoviral
particles and analysed after two days for ZBED6, IGF2 and PTTG1
mRNA expression levels. Results are normalised to β-actin mRNA and
expressed as a ratio to control virus. *p < 0.05 vs control virus for 3–4
independent experiments. (c, d) Control and ZBED6 overexpressing
EndoC-βH1 cells were cultured for 48 h and then pre-incubated at 5.6
mmol/l glucose for 1 h prior to measuring mitochondrial respiration with
or without 100 ng/ml IGF2 using the Seahorse technique. Basal OCR,
maximal OCR (after FCCP addition) and ECAR were calculated. (c)
Representative OCR recordings in which each line represents 6–10
replicates, and (d) the results from five independent experiments as
means ± SEM. *p < 0.05 vs corresponding no IGF2 treatment cells. †p
< 0.05 vs corresponding control virus cells. (e, f) Control and ZBED6
overexpressing EndoC-βH1 cells were incubated in the absence and
presence of palmitate (1.5 mmol/l in 2% BSA) and high glucose (20
mmol/l) for 1 h during measurement of mitochondrial respiration.
Results are mean ± SEM of five independent experiments. *p < 0.05 vs
corresponding no treatment cells. † denotes p < 0.05 vs corresponding
control virus cells. (g) EndoC-βH1 cells were transduced with ZBED6
adenoviral vectors at 10 and 50 MOI and then cell cycle phases were
analysed by flow cytometry 2 days later. Results are mean ± SEM of five
independent experiments. ***p < 0.001 vs corresponding control cells.
(h) EndoC-βH1 cells were transduced with ZBED6 adenoviral vectors at
10 and 50MOI and then analysed by flow cytometry 3 days later. Results
are mean ± SEM of five independent experiments. *p < 0.05 vs
corresponding control cells. (i) Human islets were dispersed by trypsin
treatment and then transduced with ZBED6 adenoviral vectors at 10 and
50 MOI. Three days later cells were exposed to 1.7 and 17 mmol/l
glucose and the insulin release was analysed by ELISA. Results are
mean ± SEM of six independent experiments using islets from two
human donors. *p < 0.05 vs corresponding control cells. (j) Insulin
release data from (i) were used to calculate the glucose-stimulated
insulin release expressed as ratio 17 mmol/l (high) glucose to 1.7
mmol/l (low) glucose. *p < 0.05 vs corresponding control cells
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fluorescence both at basal conditions and after 30 and 60 min of
stimulation with palmitate and high glucose (Fig. 4e).
The MIN6 cells were also used for analysis of mito-
chondrial ROS production using the MitoSOX probe.
The MIN6 sh1 cells produced more mitochondrial
ROS, both at basal and palmitate stimulated conditions,
than neg cells (Fig. 4f).
ZBED6 reduces the expression of the mitochondrial regulator
PRC As ZBED6-restricted mitochondrial activity is not restored
by exogenous IGF2,we looked for other ZBED6 targets. ZBED6
binds with moderate strength to the PPAR coactivator-1 (PRC)
promoter region in MIN6 cells, but very weakly in C2C12
myotube cells [25] (ESM Fig. 2). PRC, together with PGC-1α
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known activators of mitochondrial protein transcription [26]. In
ZBED6-overexpressing EndoC-βH1 cells, PRC levels were
lowered at basal conditions and after culture for 24 h in
the presence of palmitate and high glucose (Fig. 4g,h).
In MIN6 sh1 cells (Zbed6-knockdown), PRC was
increased at basal conditions (Fig. 4h), suggesting that
ZBED6 controls PRC levels in beta cells.
Knockdown of PRC results in lowered basal and maximal OCR
We next performed RNA interference (RNAi) to downregulate
PRC protein levels in EndoC-βH1 cells. In a small interfering
RNA (siRNA) titration experiment, we observed after 2 and 3
days an approximate 40–50% lowering of the PRC protein
(ESMFig. 5). In such PRC knockdown cells, basal and maximal
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treatment (Fig. 4i). PRC knockdown did not affect ECAR,
suggesting that ZBED6 suppresses mitochondrial function by
reducing PRC levels.
Discussion
ZBED6 is a transcriptional regulator that represses postna-
tal IGF2 expression [3]. However, we report here an unal-
tered beta cell area in IGF2 overexpressing WT G/A mice.
It is therefore likely that ZBED6-dependent IGF2 expres-
sion is without physiological consequence for beta cells,
and that the observed ZBED6-induced effects were instead
due to other growth-controlling genes. One such gene,
which contains ZBED6 binding sites in its promoter/
enhancer region and which is downregulated in Zbed6-
KO mice, is Pttg1. The Pttg1 gene product modulates
G1/S cell phase transition [27], functions as a securin
during chromosome separation [28] and is required for
beta cell development and proliferation [29]. It is therefore
possible that ZBED6, by enhancing expression of this and
other growth-controlling genes, maintains normal beta cell
replication, ensuring an adequate beta cell mass for the
long-term preservation of glucose tolerance. Interestingly,
ZBED6 expression appears to be reduced in human beta
cells with increasing age [30].
The lowered beta cell mass of Zbed6-KO mice did not
promote glucose intolerance when given an CD, but as the
mice were of the Nnt+/Nnt+ genotype, a milder beta cell
phenotype can be expected [21]. Therefore, it is not surprising
that the lowered beta cell mass, without HFD treatment, did
not provoke glucose intolerance. However, in Zbed6-KO
(Nnt+/Nnt+) mice fed an HFD, glucose intolerance developed,
suggesting that the combination of a reduced beta cell
mass and a diet overload is necessary to cause impaired
beta cell function.
A clue to why Zbed6-KO promotes impaired glucose toler-
ance in HFD-treated mice may be that the expression of islet
oxidative phosphorylation genes was increased in vivo.
Interestingly, Zbed6 knockdown increased and ZBED6 over-
expression decreased OCR in vitro, clearly supporting the
in vivo results. Mitochondrial respiration is regulated by
members of the PPAR coactivator family PRC, PGC-1α and
PGC-1β [26]. Human islets express high levels of PRC (6.8
reads per kilobase million [RPKM]), intermediate levels of
PGC-1α (2.6 RPKM) and low levels of PGC-1β (0.3
RPKM) [31], and ZBED6 binds to the PRC promoter in beta
cells [6]. In line with this, PRC protein levels were increased
by Zbed6-KO and decreased by ZBED6 overexpression, and
PRC knockdown resulted in reduced OCR. This suggests that
PRC is an important mitochondrial regulator in human beta
Fig. 4 ZBED6 overexpression in EndoC-βH1 cells results in lowered J-
aggregate fluorescence, MitoTracker Red uptake and mitochondrial ROS
production. Downregulation of ZBED6 results in increased OCR, ECAR,
J-aggregate fluorescence and mitochondrial ROS production. ZBED6
overexpression reduces expression level of PRC, and ZBED6
downregulation increases expression level of PRC. (a) A fluorescence
microscopic image with JC-1 staining (3 μmol/l for 10 min, red colour)
of EndoC-βH1 cells showing three ZBED6-GFP-positive cells (green
colour, arrows) with no active mitochondria, one ZBED6-GFP-positive
cell with active mitochondria (green, block head). Scale bar, 10 μm.
Confocal image showing MitoTracker Red staining (10 μmol/l for 10
min, red colour) of a ZBED6-GFP expressing cell (green nucleus)
surrounded by non-transfected cells. The dotted line shows the probable
cell membrane position of the ZBED6-GFP-positive cell. Scale bar, 50
μm. (b) Left axis: quantification of J-aggregate positive mitochondrial
structures in GFP-positive and GFP-negative cells. Results are means
from 21 (GFP-negative) and 29 (GFP-positive) cells obtained from six
randomly photographed culture plate areas. Right axis: quantification of
Mitotracker Red signal in GFP-positive and GFP-negative cells. Results
are means from ten randomly photographed GFP-positive cells with an
adjacent GFP-negative cell. (c) MitoSOX fluorescence in EndoC-βH1
control and ZBED6 overexpressing cells quantified by flow cytometry.
Cells were cultured for 24 h at standard conditions (5 mmol/l glucose,
control) or supplemented with 0.5 mmol/l palmitate + 20 mmol/l glucose
(P+HG), and then labelled for 40 min with 1 μmol/l of the MitoSOX
probe. Results are means ± SEM for six independent experiments. *p <
0.05. (d) Control and Zbed6 knockdown (ZBED6 KD) MIN6 cells were
cultured for 24 h in 5 mmol/l (G5) or 25 mmol/l (G25) glucose and then
pre-incubated at 5.6 mmol/l glucose for 1 h prior to measuring
mitochondrial respiration at 5 mmol/l (G5) or 25 mmol/l (G25) glucose
using the Seahorse technique. Basal OCR, maximal OCR (after FCCP
addition) and ECAR were calculated. Results are from six independent
experiments. *p < 0.05 vs corresponding control cells. (e) βTC-6 cells
treated with scrambled shRNA lentiviral particles (negative control; neg)
or with two different anti-Zbed6 shRNA lentiviral particles (sh1 and sh2)
were labelled with 3 μmol/l JC-1 for 10 min and then treated with 0.5
mmol/l palmitate +25 mmol/l glucose (P+HG) for 0, 30 or 60 min. J-
aggregate fluorescence was obtained by flow cytometry analysis and by
calculation of the FL2/FL1 (590/530 nm) ratio. Results are means ± SEM
for three experiments. (f) MitoSOX fluorescence in MIN6 control and
ZBED6 KD cells quantified by flow cytometry. Cells were cultured for
24 h under standard conditions (25 mmol/l glucose, control) or
supplemented with 0.5 mmol/l palmitate + 25 mmol/l glucose
(P+HG), and then labelled for 40 min at 1 μmol/l MitoSOX probe.
Results are means ± SEM for five independent experiments. *p < 0.05.
(g−i) ZBED6 overexpression reduces and ZBED6 downregulation
increases expression level of PRC. (g) Control and ZBED6
overexpressing EndoC-βH1 cells were cultured for 48 h and then
treated with or without mouse IGF2 (100 ng/ml) or the combination
palmitate (1.5 mmol/l in 2% BSA) and high glucose (20 mmol/l) for 3
h. The expression level of PRC was measured by immunoblotting
analysis. Results are normalised to α-tubulin (Tub) expression level and
are expressed as means ± SEM for 6–13 independent experiments. *p <
0.05. (h) MIN6 cells expressing scramble shRNA (neg) or anti-Zbed6
shRNA (sh1) were analysed for PRC expression using immunoblot
analysis. Cells were cultured for 24 h in the presence of 5 mmol/l
glucose (G5), 5 mmol/l glucose + 0.5 mmol/l palmitate (G5+P), 25
mmol/l glucose (G25) or 25 mmol/l glucose + 0.5 mmol/l palmitate
(G25+P). Results are from 3–4 independent experiments. (i)
Knockdown of PRC results in reduced basal and maximal OCR.
EndoC-βH1 cells were transfected with 50 nmol/l siRNA targeting to
PRC and then were analysed for OCR using the Seahorse technique.
Results are from four independent experiments. *p < 0.05 vs control
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cells, and that ZBED6 may control expression of this PPAR
coactivator via a direct interaction with the PRC gene
promoter/enhancer region. PRC has, to our knowledge, not
been investigated in beta cells. Additionally, in other
cell types PRC is rather poorly characterised, but it
has been proposed that PRC acts rapidly upon extracel-
lular signals, for example growth factor stimulation, to
increase mitochondrial biogenesis [26].
There seems to exist a correlation between maximal OCR,
inner membrane hyperpolarisation and mitochondrial ROS
production, as all three variables were increased by the nutri-
ents palmitate and high glucose. Indeed, it is known that mito-
chondria of primary beta cells respond to nutrients with stim-
ulation of the Krebs cycle and the respiratory chain [32].
Furthermore, in vitro addition of metabolites, ADP and
uncouplers results in superoxide and hydrogen peroxide leak-
age from the respiratory complexes, and this occurs via chem-
ical reduction of electron leaking sites and a strong
protonmotive force [33–35]. Excess nutrients also evoke an
increased functional demand (higher need for insulin produc-
tion), which consumes ATP and increases ADP levels [35],
further stimulating the respiratory chain.Moreover, our results
demonstrate that mitochondria are activated by the PRC gene,
a process controlled by ZBED6. Thus, it seems that overnu-
trition predisposes for augmented beta cell ROS production,
and in the case when ZBED6 does not restrict mitochondrial
activation by dampening PRC gene expression, potentially
harmful levels of ROS may be generated. High mitochondrial
ROS levels cause beta cell dysfunction [36, 37], and the pres-
ent ROS increase, in response to nutrients and Zbed6-KO,
could therefore explain, at least in part, why Zbed6-KO mice
become glucose intolerant when given an HFD.
Type 2 diabetes is associated with beta cell loss of identity,
dedifferentiation or beta to alpha cell transdifferentiation [10,
38], and can in later stages often result in loss of transcription
factors such as MafA, Nkx6-1 and Pdx1 [10]. Interestingly, in
this study we observed the opposite, namely increased expres-
sion of beta cell-specific genes during conditions of glucose
intolerance. In addition, important beta cell autoantigens in
type 1 diabetes were also increased. Thus, Zbed6-KO in func-
tionally challenged mice promoted a beta cell hyper-
differentiated and hyper-immunogenic state that mediates
not only a higher insulin production, but also might facilitate
inflammatory/autoimmune reactions. It is not clear why beta
cells of glucose-intolerant Zbed6-KO mice become hyper-
differentiated rather than dedifferentiated, but it could be
envisaged that the islet cells were in an early stage of meta-
bolic stress and still had not started the process of trans-/dedif-
ferentiation [38].
A limitation of this study is that a global knockout was
used, making it harder to pinpoint whether ZBED6 affects
beta cells directly or via other organs/cell types. Another limi-
tation is that the in vitro techniques were not easily adapted for
the in vivo situation. Nevertheless, ZBED6 appears to perform
an important function in balancing differentiation vs prolifer-
ation. This could promote a more sustainable beta cell pheno-
type in which mitochondrial ROS production is restrained.
The role of ZBED6 in the pathophysiology of type 2 diabetes
remains to be clarified, but it is tempting to speculate that
ZBED6 maintains beta cell survival and proliferation at the
cost of decreased insulin production, and that this is beneficial
during long-term high-fat overfeeding.
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